MedTrace Logo

Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19.

NCT05433298 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2025-02-10

No results posted yet for this study

Summary

The purpose of this study is evaluate the feasibility, safety and potential efficacy of an advanced cell therapy product for the treatment of patients with SARS-CoV-2 pneumonia.

Conditions

Interventions

BIOLOGICAL

Mesenchymal stem cell

Administration of advanced cell product

OTHER

Placebo

Ringer's lactate, albumin and heparin solution

Sponsors & Collaborators

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

    collaborator OTHER_GOV

  • Paulo Brofman

    lead OTHER

Principal Investigators

  • Paulo R Brofman, phD · Pontifícia Universidade Católica do Paraná

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2022-11-26
Completion
2023-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05433298 on ClinicalTrials.gov